Forex
World
Market
Business
Cryptocurrency
Commodities
MAP
Publish for free
Business
financetom
/
Business
/
--Deere Keeps Quarterly Dividend at $1.47 a Share; Payable Nov. 8 to Shareholders on Sept. 30
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
Forex
Stocks Market
Commodities
--Deere Keeps Quarterly Dividend at $1.47 a Share; Payable Nov. 8 to Shareholders on Sept. 30
Aug 28, 2024 9:21 AM
11:51 AM EDT, 08/28/2024 (MT Newswires) --
Price: 378.13, Change: +2.14, Percent Change: +0.57
Previous page:
Volcon Regains Compliance With Nasdaq's Listing Requirements -- Shares Rise
Next page:
General Mills Appoints Chief Strategy & Growth Officer
Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Release time ⇩
Release time ⇧
Like count ⇩
Show More Comments
Related Articles >
Volcon Regains Compliance With Nasdaq's Listing Requirements -- Shares Rise
Jul 18, 2024
10:55 AM EDT, 07/18/2024 (MT Newswires) -- Volcon ( VLCN ) said Thursday it has been informed by Nasdaq that it has regained compliance with the stock exchange's listing rules. The company's shares were nearly 7% higher in recent trading. Price: 3.25, Change: +0.18, Percent Change: +5.70 ...
General Mills Appoints Chief Strategy & Growth Officer
Jul 18, 2024
10:53 AM EDT, 07/18/2024 (MT Newswires) -- General Mills ( GIS ) said Thursday it has appointed Asheesh Saksena as chief strategy & growth officer, effective Aug. 26. Saksena succeeds Dana McNabb, following her prior appointment to group president, North America Retail, the firm said. He most recently served as chief growth officer for Gap (GPS). Price: 66.15, Change: +0.81,...
Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment
Jul 18, 2024
10:54 AM EDT, 07/18/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Thursday it completed enrollment in a clinical trial of zilganersen, an investigational ribonucleic acid-targeted medicine to treat children and adults with Alexander disease, a neurological disorder. Topline data are expected in H2 2025. The study is the first trial to evaluate an investigational medicine designed to address...
Bristol Myers Squibb Validates Net-Zero Goals through Science Based Targets Initiative
Jul 18, 2024
10:55 AM EDT, 07/18/2024 (MT Newswires) -- Bristol Myers Squibb ( BMY ) said Thursday it has validated its near-term and longer-term targets to lower greenhouse emissions throughout its value chain to net-zero by 2050 through the Science Based Targets initiative. The drug maker announced its net-zero goal last year and also set several interim targets, including reducing its direct...
About
Terms and Conditions
Privacy policy
Cookie Settings
Contact Us
Services
Login
register
financetom
Market
Personal Finance
Business
Economy
Cryptocurrency
MAP
Links
zpostcode
Recruit
weather
mreligion
Yellowpages
sport
constellation
shopping
name
game
directory
literature
Word
tour
furnish
Lottery
tftnews
lyrics
News
digital
car
dir
Edu
Finance
Copyright 2023-2026 -
www.financetom.com
All Rights Reserved
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
MAP